The findings of the study demonstrate that PD-L1 BiTE exhibits notable efficacy as an immunotherapy agent for killing PD-L1-positive tumor cells and macrophages, while concurrently preserving the integrity of T lymphocytes. The gene discussed is CD274; the disease is neoplasm.